However, factors predicting its development are still controversial. This study was conducted to evaluate the frequency of antituberculosis therapy-induced hepatotoxicity and the risk factors related to its development. Methods: The author reviewed retrospectively the medical records of the 2,204 patients who had taken ATT for 2 weeks or longer from January 1, 2005 through June 30, 2010 in Gyeong-Sang National university, South Korea. The patients’ demographic, social, clinical and laboratory

data were collected and analyzed for the relationships between hepatotoxicity and these various parameters. Hepatotoxicity was determined by investigation of liver tests at the time of pretreatment selleck inhibitor and 7, 14, 30, 60, and 90 days of

ATT. Results: Two-hundred two (9.2%) out of 2,204 patients taken ATT developed hepatotoxicity. Mean age of the patients with ATT-induced hepatotoxicity was 52.5 ± 18.7 years and 130 (64.6%) patients were male. The frequency of ATT-induced hepatotoxicity was higher in the patients with abnormal baseline liver function than the ones with normal liver function (88/541, 16.3% vs. 114/1,663, 6.9%, p = 0.000), hepatitis B virus (HBV) or hepatitis C virus (HCV) infected than non-infected (28/150, 18.7% vs. 174/2,054, 8.5%, p = 0.000) BMN 673 clinical trial patients, and the patients with primary hepatocellular carcinoma (HCC) than the ones without it (7/17, 41.2% vs. 195/2,187, 8.9%, p = 0.000).

There was no significant relationship between the frequency Urease of ATT-induced hepatotoxicity and gender, old age over 60 years or 35 years, body mass index, alcohol drink, indication of ATT, underlying diseases except HCC, and past history of ATT. Baseline LFT abnormality, underlying HCC and HBV or HCV infections were risk factors for ATT-induced hepatotoxicity on univariate and multivariate analysis. The majority of patients with ATT-induced hepatotoxicity (170/202, 84.2%) were identified within first 30 days of ATT, and hepatotoxicity occurred within first 7 days in 64 patients (31.7%). Conclusion: The frequency of ATT-induced hepatotoxicity was 9.2%, and its risk factors were abnormal baseline liver function, and underlying HBV or HCV infection and hepatocellular carcinoma. Closed monitoring should be required for the patients who have these risk factors during first 30 days of ATT, especially first 7 days. Key Word(s): 1. antituberculosis; 2. hepatotoxicity; 3. frequency; 4.